Abstract
Through history societies have searched for potions, elixirs, and aphrodisiacs, hoping to find a simple, effective means to enhance male sexual performance. Until recently the role of the male sexual health specialist in this matter was limited. Since the elucidation of the NO/cGMP second messenger pathway of cavernous smooth muscle, we have learned that erectile function can be enhanced with inhibition of phosphodiesterase 5 (PDE5) enzyme activity. Sildenafil citrate was the first of such agents available under US Food and Drug Administration approval, now joined by vardenafil and tadalafil. The availability of these agents has ignited a revolution in the management of erectile dysfunction (ED), resulting in the development of drugs that target other important signaling pathways. One such agent is apomorphine, a centrally acting dopaminergic drug. Thus, the previously designated first-line modalities (intracavernous injection, intraurethral suppository, vacuum constriction device) are now considered as second-line and are reserved for those in whom oral agents fail.
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Heaton JPW, Adams MA, Morales A: A therapeutic taxonomy of treatments for erectile dysfunction: an evolutionary imperative. Intl Impot Res 1997, 9: 117–121.
Morales A, Heaton JPW: Nonsurgical treatments for erectile dysfunction: oral, topical, intracavernous, and vacuum devices. In Atlas of Clinical Urology. Edited by Vaughan ED Jr., Perlmutter AP. Philadelphia: Current Medicine, Inc.; 1999:4. 1–4. 13.
Guiliano F, Montorsi F, Mirone V, et al Switching from intracavernous prostaglandin El injections to oral sildenafil citrate in patients with erectile dysfunction: results of a multicenter European study. J Urol 2000, 164:708–711.
Burnett AL: Nitric oxide in the penis: physiology and pathology. J Urol 1997, 157: 320–324.
Carson CC, Burnett AL, Levine LA, Nehra A: The efficacy of sildenafil citrate (Viagra®) in clinical populations: an update. Urology2002, 60 (suppl 2B ): 12–27.
Hellstrom WJG, Gittelman M, Karlin G, etal: Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. JAndrol2002, 23: 763–771.
Brock GB, McMahon CG, Chen KK, et al Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Uro12002, 168 (4 pt 1):1332–1336.
Heaton JWP, Morales A, Adams M, et al Resolution of erectile failure after oral treatment with apomorphine. Urology 1995, 45:200–203.
WHO International Society for Impotence Research: Oral non-endocrine treatment. In Erectile Dysfunction http://www.issir.org.
Paoletti R: Biochemistry and pharmacology of prostaglandin El: introductory remarks. In Prostaglandin El in Atherosclerosis. Edited by Sinzinger E, Rogatti W. New York: Springer-Verlag; 1986: 3–7.
Molderings GJ, Van Ahlen H, Gothert M: Modulation of noradrenaline release in human corpus cavernosum by presynaptic prostaglandin receptors. Intl Impot Res 1992, 4: 19.
Kifor J, Williams GH, Vickers MA, et al Tissue angiotensin lI as a modulator of erectile function: I. Angiotensin peptide content, secretion and effects in the corpus cavernosum. J Urol 1997, 157:1920–1925.
Zhang P, Christ GJ, Brink PR: PGE1-induced alterations in Maxi-K+ channel activity in cultured human corporal smooth muscle cells. J Urol 1995, 155 (suppl 6): 78A.
Lue TF: Male sexual dysfunction. In Smith’s General Urology, edn 15. Edited byTanagho EA, McAninch JW. New York: McGraw-Hill/Appleton & Lange; 2001: 788–810.
Porst H: Vasoactive substances in erectile dysfunction: a survey of 10 years global experience. In Penile Disorders. Edited by Porst H. Berlin: Springer-Verlag; 1977: 175–196.
Bresolle F, Costa P, Rouzier-Panis R, et al Pharmacokinetics of moxisylyte in healthy volunteers after intracavernous injection of increasing doses. EurJ Clin Pharmacol 1996, 49:411–415.
Porst H: The rationale for prostaglandin El in erectile failure: a survey of world-wide experience. J Urol 1996, 155: 802–815.
Porst H, BuvatJ, Meuleman E, etal: Intracavernous alprostadil alfadex: an effective and well tolerated treatment for erectile dysfunction. Results of a long-term European study. Intl Impot Res 1998, 10: 225–231.
Valdevenito R, Melman A: Intracavernous self-injection pharmacotherapy program: analysis of results and complications. Intl Impot Res 1993, 150: 1822–1824.
Goldstein I, Borges FD, Fitch WP, et al Rescuing the failed papaverine/phentolamine erection: a proposed synergistic action of papaverine, phentolamine and prostaglandin El. J Urol 1990, 143:304A (abstract 463).
WHO International Society for Impotence Research: Table 9–3, Incidence of pain with trimix. In Erectile Dysfunction http://www.issir.org.
Stack) W, Hasun R, Marberger M: Intracavernous injection of prostaglandin El in impotent men. J Urol 1988, 140: 66.
Lee LM, Stevenson RWD, Szadz G: Prostaglandin El versus phentolamine/papaverine for the treatment of erectile impotence: a double-blind comparison. J Urol 1989, 141: 549.
WHO International Society for Impotence Research: Table 9–4, Penile scarring with trimix. In Erectile Dysfunction http://www.issir.org.
Manning M, Junemann KP: Pharmacotherapy of erectile dysfunction. In Male Infertility and Sexual Dysfunction. Edited by Hellstrom WJG. New York: Springer-Verlag; 1997: 440–451.
Padma-Nathan H, Hellstrom WJG, Kaiser FE, et al Treatment of men with erectile dysfunction with transurethral alprostadil. N Engl J Med 1997, 336:1–7.
Lewis R: Twenty years of vacuum therapy for erectile dysfunction in the United States. In Penile Disorders. Edited by Porst H. Berlin: Springer-Verlag; 1997: 162–174.
Nadig PW: Vacuum erection devices: a review. World J Urol 1990, 8: 114–118.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer Science+Business Media New York
About this chapter
Cite this chapter
Kuan, J.K., Brock, G.B. (2004). Pharmacotherapy and External Devices for Erectile Dysfuncton. In: Lue, T.F. (eds) Atlas of Male Sexual Dysfunction. Current Medicine Group, London. https://doi.org/10.1007/978-1-4613-1087-7_6
Download citation
DOI: https://doi.org/10.1007/978-1-4613-1087-7_6
Publisher Name: Current Medicine Group, London
Print ISBN: 978-1-4757-0811-0
Online ISBN: 978-1-4613-1087-7
eBook Packages: Springer Book Archive